163 related articles for article (PubMed ID: 32809265)
1. Evaluation of NR4A3 immunohistochemistry (IHC) and fluorescence in situ hybridization and comparison with DOG1 IHC for FNA diagnosis of acinic cell carcinoma.
Skaugen JM; Seethala RR; Chiosea SI; Landau MS
Cancer Cytopathol; 2021 Feb; 129(2):104-113. PubMed ID: 32809265
[TBL] [Abstract][Full Text] [Related]
2. NR4A3 Immunohistochemistry Reliably Discriminates Acinic Cell Carcinoma from Mimics.
Wong KS; Mariño-Enriquez A; Hornick JL; Jo VY
Head Neck Pathol; 2021 Jun; 15(2):425-432. PubMed ID: 32910350
[TBL] [Abstract][Full Text] [Related]
3. [Expression of NR4A3/NOR-1 in acinic cell carcinoma of the salivary gland].
Cheng K; Wang X; Wei X; Ma J; Xia QY; Shi QL; Zhou XJ; Rao Q
Zhonghua Bing Li Xue Za Zhi; 2020 Nov; 49(11):1142-1146. PubMed ID: 33152819
[No Abstract] [Full Text] [Related]
4. Nuclear NR4A3 Immunostaining Is a Specific and Sensitive Novel Marker for Acinic Cell Carcinoma of the Salivary Glands.
Haller F; Skálová A; Ihrler S; Märkl B; Bieg M; Moskalev EA; Erber R; Blank S; Winkelmann C; Hebele S; Baněčková M; Wiemann S; Müller S; Zenk J; Eils R; Iro H; Hartmann A; Agaimy A
Am J Surg Pathol; 2019 Sep; 43(9):1264-1272. PubMed ID: 31094928
[TBL] [Abstract][Full Text] [Related]
5. NR4A3 Immunostain Is a Highly Sensitive and Specific Marker for Acinic Cell Carcinoma in Cytologic and Surgical Specimens.
Viswanathan K; Beg S; He B; Zhang T; Cantley R; Lubin DJ; Shi Q; Maleki Z; Asiry S; Rao R; Katabi N; Nakaguro M; Faquin WC; Sadow PM; Siddiqui MT; Scognamiglio T
Am J Clin Pathol; 2022 Jan; 157(1):98-108. PubMed ID: 34508546
[TBL] [Abstract][Full Text] [Related]
6. NOR-1 distinguishes acinic cell carcinoma from its mimics on fine-needle aspiration biopsy specimens.
Nguyen L; Chopra S; Laskar DB; Rao J; Lieu D; Chung F; Kim ED; de Peralta-Venturina M; Bose S; Balzer B
Hum Pathol; 2020 Aug; 102():1-6. PubMed ID: 32416209
[TBL] [Abstract][Full Text] [Related]
7. NR4A3 (NOR-1) Immunostaining Shows Better Performance than DOG1 Immunostaining in Acinic Cell Carcinoma of Salivary Gland: a Preliminary Study.
Owosho A; Tyler D; Adesina O; Odujoko O; Summersgill K
J Oral Maxillofac Res; 2021; 12(1):e4. PubMed ID: 33959239
[TBL] [Abstract][Full Text] [Related]
8. Utility of an immunocytochemical analysis for pan-Trk in the cytodiagnosis of secretory carcinoma of the salivary gland.
Ito H; Ishida M; Ebisu Y; Okano K; Sandoh K; Noda Y; Miyasaka C; Fujisawa T; Yagi M; Iwai H; Tsuta K
Diagn Cytopathol; 2021 Aug; 49(8):E329-E335. PubMed ID: 33885200
[TBL] [Abstract][Full Text] [Related]
9. Enhancer hijacking activates oncogenic transcription factor NR4A3 in acinic cell carcinomas of the salivary glands.
Haller F; Bieg M; Will R; Körner C; Weichenhan D; Bott A; Ishaque N; Lutsik P; Moskalev EA; Mueller SK; Bähr M; Woerner A; Kaiser B; Scherl C; Haderlein M; Kleinheinz K; Fietkau R; Iro H; Eils R; Hartmann A; Plass C; Wiemann S; Agaimy A
Nat Commun; 2019 Jan; 10(1):368. PubMed ID: 30664630
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic role of DOG1 and p63 immunohistochemistry in salivary gland carcinomas.
Abd Raboh NM; Hakim SA
Int J Clin Exp Pathol; 2015; 8(8):9214-22. PubMed ID: 26464669
[TBL] [Abstract][Full Text] [Related]
11. NR4A3 Expression Is Consistently Absent in Acinic Cell Carcinomas of the Breast: A Potential Nosologic Shift.
Richardson ET; Selenica P; Pareja F; Cin PD; Hanlon E; Weigelt B; Reis-Filho JS; Hornick JL; Jo VY; Schnitt SJ
Mod Pathol; 2023 Jun; 36(6):100144. PubMed ID: 36828363
[TBL] [Abstract][Full Text] [Related]
12. Analysis of clinicopathologic features and expression of NR4A3 in sinonasal acinic cell carcinoma.
Wang H; Zhai C; Zhang C; Liu Q; Zhang H; Sun X; Lin L; Yu H; Wang D
Mod Pathol; 2022 May; 35(5):594-600. PubMed ID: 34873305
[TBL] [Abstract][Full Text] [Related]
13. PON3::LCN1 and HTN3::MSANTD3 Gene Fusions With NR4A3/NR4A2 Expression in Salivary Acinic Cell Carcinoma.
Zhu L; Sun L; Zhang Y; Liu X; Li X; Zhou Z; Cui Y; Zhou CX; Li TJ
Am J Surg Pathol; 2024 Jun; 48(6):681-690. PubMed ID: 38682454
[TBL] [Abstract][Full Text] [Related]
14. Lysozyme Expression Can be Useful to Distinguish Mammary Analog Secretory Carcinoma from Acinic Cell Carcinoma of Salivary Glands.
Mariano FV; Gómez CA; de Souza do Nascimento J; Dos Santos HT; Egal ES; Montalli VA; Vargas PA; de Almeida OP; Altemani A
Head Neck Pathol; 2016 Dec; 10(4):429-436. PubMed ID: 27177644
[TBL] [Abstract][Full Text] [Related]
15. DOG1: a novel marker of salivary acinar and intercalated duct differentiation.
Chênevert J; Duvvuri U; Chiosea S; Dacic S; Cieply K; Kim J; Shiwarski D; Seethala RR
Mod Pathol; 2012 Jul; 25(7):919-29. PubMed ID: 22460810
[TBL] [Abstract][Full Text] [Related]
16. Combined DOG1 and Mammaglobin Immunohistochemistry Is Comparable to ETV6-breakapart Analysis for Differentiating Between Papillary Cystic Variants of Acinic Cell Carcinoma and Mammary Analogue Secretory Carcinoma.
Said-Al-Naief N; Carlos R; Vance GH; Miller C; Edwards PC
Int J Surg Pathol; 2017 Apr; 25(2):127-140. PubMed ID: 27670353
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemistry with a pan-TRK antibody distinguishes secretory carcinoma of the salivary gland from acinic cell carcinoma.
Hung YP; Jo VY; Hornick JL
Histopathology; 2019 Jul; 75(1):54-62. PubMed ID: 30801752
[TBL] [Abstract][Full Text] [Related]
18. Fine-needle aspiration features of extraskeletal myxoid chondrosarcoma: A study of cytological and molecular features.
Santos F; Martins C; Lemos MM
Diagn Cytopathol; 2018 Nov; 46(11):950-957. PubMed ID: 30353688
[TBL] [Abstract][Full Text] [Related]
19. Cytopathologic features of mammary analogue secretory carcinoma.
Bishop JA; Yonescu R; Batista DA; Westra WH; Ali SZ
Cancer Cytopathol; 2013 May; 121(5):228-33. PubMed ID: 23042752
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemistry surrogates for molecular alterations: A new paradigm in salivary gland tumor cytopathology?
Bishop JA
Cancer Cytopathol; 2021 Feb; 129(2):102-103. PubMed ID: 32809250
[No Abstract] [Full Text] [Related]
[Next] [New Search]
